Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

PSA Level Greater Than Two 1Hormone Sensitive Prostate Cancer 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leuprolide × 30 days × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

NCT00544830 2026-05-15

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
29 enrolled 12 charts
Genitourinary

PSA Level Greater Than Two

Data powered by HemOnc (CC BY 4.0) Colophon âš¡